Our latest deals : Domain Therapeutics ($42M series A), Ludocare (€4.2M Seed), Spine Innovations (M&A sell-side, un-disclosed amount), Neurofenix ($7M series A), Incepto (€27M series B)
Telemedicine at the service of patients 🚀
We’re proud to announce a partnership with TeleClinic, Germany’s market leader for online consultations.
🇺🇸 After expanding to six countries this year, Vik Atopic Dermatitis completes the world tour with one more launch: the USA!
PKvitality’s mission is to enable everyone to contribute actively to their well-being and health through products that are simple and comfortable to use. Thus, its K’Watch Glucose smartwatch will be the world’s first CGM device that will track glucose levels discreetly and continuously at the wrist.
Paris, France, July 21, 2022 – 7:00 PM CEST – ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical-stage biotechnology company developing innovative drugs for the treatment of cardiovascular emergencies, in particular stroke, announced today that it has received “PRIority Medicines” status from the European Medicines Agency (EMA) for its drug candidate, glenzocimab, for the treatment of patients with stroke.
Incepto is the European platform for applied AI: unified, secure and seamlessly integrated into your clinical workflows and your workstations (RIS/PACS/Viewer).
Subtle Medical, a healthcare technology company improving the quality and efficiency of medical imaging, announced they are expanding their partnership with Incepto, a leading platform of artificial intelligence solutions for radiology professionals in Europe, by offering their AI applications, SubtleMR and SubtlePET on Incepto’s platform.
Founded in 2018, Incepto is a unique platform on the market that offers doctors and hospitals access to a portfolio of solutions based on artificial intelligence, designed to improve the quality of diagnoses, and save time for medical teams, without having to change equipment. In order to support its growth at a European scale, Incepto is raising €27 million today.
FineHeart certified ISO 13485 : 2016 for Medical Device Quality Management Systems
Bordeaux, France, September 5, 2022 – FineHeart S.A, a preclinical medical device company that has developed the ICOMS FLOWMAKER®, a fully Implantable Cardiac Output Management System designed to address the unmet need of patients suffering from severe heart failure, today announced its ISO 13485 : 2016 certification. This certifies the compliance of FineHeart’s quality management system with medical device industry regulations and has been issued following an audit by BSI, the independent, internationally recognized, accreditation organization.
Neurofenix secures $7million to fuel expansion
Digital neuro-rehabilitation platform Neurofenix, which is helping to revolutionise remote rehabilitation for stroke patients, has secured $7million to help fuel its expansion and fund clinical trials in the United States.
Latest Insights
(Inhale, exhale) It’s with great joy that we announce our partnership with Petit BamBou, an application dedicated to meditation and relaxation.
Paris, October 16, 2018 – Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including
Paris, January 28, 2022 – PKvitality, a French company specializing in bio-wearables, finalized a funding round of €6m, including an investment from the EIC Fund (European Innovation Council Fund). Other contributors to this round are Business Angels, EIT Health, alongside current investors on board, including Beurer GmbH. This round will accelerate the development of K’Watch Glucose, a Continuous Glucose Monitor (CGM) embedded in a smartwatch for diabetes patients.
Digital neuro-rehabilitation platform Neurofenix, which is helping to revolutionise remote rehabilitation for stroke patients, has secured $7million to help fuel its expansion and fund clinical trials in the United States.
Archamps, June 29th
, 2022 – Cathay Capital announced its investment in TransCure bioServices, alongside the management team and Financière Arbevel. With this transaction, TransCure bioServices will benefit from Cathay Capital’s healthcare expertise as well as its strategic, and financial support to accelerate its growth and global expansion